AbbVie: Why The Company Is Still Overvalued (NYSE:ABBV)

0
88


Facial aesthetics surgery treatment

Group4 Studio

On February 9, 2023, AbbVie (NYSE:ABBV) will report full-year and fourth-quarter 2022 financial results. Reporting results in the second week of February is an unusual practice for major pharmaceutical companies and even more so for AbbVie. The company’s

Source: Author's elaboration, based on Investing.com

Source: Author’s elaboration, based on Investing.com

Source: Author's elaboration, based on quarterly securities report

Source: Author’s elaboration, based on quarterly securities report

Source: Author's elaboration, based on quarterly securities reports

Source: Author’s elaboration, based on quarterly securities reports

Source: Author's elaboration, based on quarterly securities reports

Source: Author’s elaboration, based on quarterly securities reports

Source: Author's elaboration, based on quarterly securities report

Source: Author’s elaboration, based on quarterly securities report

Source: Nathan Aisenstadt - Seeking Alpha

Source: Nathan Aisenstadt – Seeking Alpha



Source link